LUC7L2

Summary

LUC7L2 (LUC7 like 2, pre-mRNA splicing factor, HGNC:21608) is a protein-coding gene on chromosome 7q34, encoding Putative RNA-binding protein Luc7-like 2 (Q9Y383). May bind to RNA via its Arg/Ser-rich domain. It is a selective cancer dependency (DepMap: 17.1% of cell lines).

This gene encodes a protein that contains a C2H2-type zinc finger, coiled-coil region and arginine, serine-rich (RS) domain. A similar protein in mouse interacts with sodium channel modifier 1, and the encoded protein may be involved in the recognition of non-consensus splice donor sites in association with the U1 snRNP spliceosomal subunit. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 51631 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 1 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 17.1% of screened cell lines
• MANE Select transcript: NM_016019

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21608
Approved symbol	LUC7L2
Name	LUC7 like 2, pre-mRNA splicing factor
Location	7q34
Locus type	gene with protein product
Status	Approved
Aliases	CGI-74, CGI-59, H_NH0792N18.3, FLJ10657, LUC7B2, hLuc7B2
Ensembl gene	ENSG00000146963
Ensembl biotype	protein_coding
OMIM	613056
Entrez	51631

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 17 protein_coding, 3 retained_intron, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000263545, ENST00000354926, ENST00000435096, ENST00000456182, ENST00000463912, ENST00000482860, ENST00000498518, ENST00000541170, ENST00000608368, ENST00000619796, ENST00000867360, ENST00000867361, ENST00000867362, ENST00000867363, ENST00000867364, ENST00000867365, ENST00000867366, ENST00000867367, ENST00000933629, ENST00000947907, ENST00000947908, ENST00000947909, ENST00000947910

RefSeq mRNA: 3 — MANE Select: NM_016019 NM_001244585, NM_001270643, NM_016019

CCDS: CCDS43656, CCDS59085, CCDS59510

Canonical transcript exons

ENST00000354926 — 10 exons

Exon	Start	End
ENSE00001402065	139422163	139423454
ENSE00003481714	139407174	139407350
ENSE00003514400	139376062	139376156
ENSE00003530613	139412551	139412580
ENSE00003536523	139398599	139398697
ENSE00003582705	139359894	139360322
ENSE00003591256	139417538	139417729
ENSE00003613929	139402137	139402247
ENSE00003616162	139405644	139405787
ENSE00003657081	139409563	139409654

Expression profiles

Bgee: expression breadth ubiquitous, 287 present calls, max score 98.95.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 83.9873 / max 1324.6369, expressed in 1827 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
81446	80.0280	1827
81447	2.3350	998
81448	0.7550	331
81445	0.5983	365
81449	0.2711	137

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	98.95	gold quality
left lobe of thyroid gland	UBERON:0001120	98.41	gold quality
right lobe of thyroid gland	UBERON:0001119	98.38	gold quality
right uterine tube	UBERON:0001302	98.34	gold quality
mucosa of stomach	UBERON:0001199	98.26	gold quality
calcaneal tendon	UBERON:0003701	98.03	gold quality
nerve	UBERON:0001021	98.00	gold quality
tibial nerve	UBERON:0001323	98.00	gold quality
thyroid gland	UBERON:0002046	97.89	gold quality
endocervix	UBERON:0000458	97.69	gold quality
left uterine tube	UBERON:0001303	97.64	gold quality
ventricular zone	UBERON:0003053	97.64	gold quality
descending thoracic aorta	UBERON:0002345	97.62	gold quality
right lung	UBERON:0002167	97.58	gold quality
body of pancreas	UBERON:0001150	97.56	gold quality
body of uterus	UBERON:0009853	97.55	gold quality
tibial artery	UBERON:0007610	97.52	gold quality
popliteal artery	UBERON:0002250	97.51	gold quality
skin of abdomen	UBERON:0001416	97.45	gold quality
ectocervix	UBERON:0012249	97.43	gold quality
skin of leg	UBERON:0001511	97.36	gold quality
left ovary	UBERON:0002119	97.33	gold quality
right ovary	UBERON:0002118	97.31	gold quality
aorta	UBERON:0000947	97.30	gold quality
right coronary artery	UBERON:0001625	97.19	gold quality
thoracic aorta	UBERON:0001515	97.18	gold quality
ascending aorta	UBERON:0001496	97.16	gold quality
metanephros cortex	UBERON:0010533	97.09	gold quality
tendon	UBERON:0000043	97.06	gold quality
muscle layer of sigmoid colon	UBERON:0035805	97.00	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.57

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

79 targeting LUC7L2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-7978	99.86	66.90	856
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-520F-3P	99.82	71.32	1216
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 17.1% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 4)

• Loss of LUC7L2 is associated with myeloid neoplasms. (PMID:24429498)
• Functional analyses of human LUC7-like proteins involved in splicing regulation and myeloid neoplasms. (PMID:33852859)
• Loss of LUC7L2 and U1 snRNP subunits shifts energy metabolism from glycolysis to OXPHOS. (PMID:33852893)
• Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2-Mediated MLH1 Intron Retention. (PMID:38477507)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	zgc:158803	ENSDARG00000019765
mus_musculus	Luc7l2	ENSMUSG00000029823
rattus_norvegicus	Luc7l2	ENSRNOG00000006001
drosophila_melanogaster	CG7564	FBGN0036734
caenorhabditis_elegans		WBGENE00015207

Paralogs (2): LUC7L (ENSG00000007392), LUC7L3 (ENSG00000108848)

Protein

Protein identifiers

Putative RNA-binding protein Luc7-like 2 — Q9Y383 (reviewed: Q9Y383)

All UniProt accessions (3): Q9Y383, F8WEU3, V9GZ75

UniProt curated annotations — full annotation on UniProt →

Function. May bind to RNA via its Arg/Ser-rich domain.

Subunit / interactions. Interacts with SCNM1.

Subcellular location. Nucleus speckle. Nucleus. Nucleoplasm.

Similarity. Belongs to the Luc7 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9Y383-1	1	yes
Q9Y383-2	2
Q9Y383-3	3

RefSeq proteins (3): NP_001231514, NP_001257572, NP_057103* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004882	Luc7-rel	Family

Pfam: PF03194

UniProt features (17 total): compositionally biased region 4, modified residue 3, splice variant 2, mutagenesis site 2, sequence conflict 2, chain 1, region of interest 1, sequence variant 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y383-F1	65.77	0.07

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 18, 266, 269

Mutagenesis-validated functional residues (2):

Position	Phenotype
266	induces a decrease in lysyl-hydroxylation. abolishes lysyl-hydroxylation; when associated with r-269.
269	induces a decrease in lysyl-hydroxylation. abolishes lysyl-hydroxylation; when associated with r-266.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 204 (showing top): MYAATNNNNNNNGGC_UNKNOWN, E2F_Q4_01, GCM_GSPT1, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GGGTGGRR_PAX4_03, GTGCCTT_MIR506, ONKEN_UVEAL_MELANOMA_UP, FREAC3_01, BLALOCK_ALZHEIMERS_DISEASE_UP, WTGAAAT_UNKNOWN, ATTACAT_MIR3803P, GOBP_PROTEIN_RNA_COMPLEX_ORGANIZATION, GOBP_RNA_SPLICING, GOBP_MRNA_SPLICE_SITE_RECOGNITION

GO Biological Process (1): mRNA splice site recognition (GO:0006376)

GO Molecular Function (4): RNA binding (GO:0003723), mRNA binding (GO:0003729), enzyme binding (GO:0019899), protein binding (GO:0005515)

GO Cellular Component (5): U1 snRNP (GO:0005685), nuclear speck (GO:0016607), U2-type prespliceosome (GO:0071004), nucleus (GO:0005634), nucleoplasm (GO:0005654)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
spliceosomal complex assembly	1
protein-RNA complex assembly	1
nucleic acid binding	1
RNA binding	1
protein binding	1
binding	1
spliceosomal snRNP complex	1
nuclear ribonucleoprotein granule	1
U2-type spliceosomal complex	1
U1 snRNP	1
U2 snRNP	1
prespliceosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1413 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LUC7L2	SCNM1	Q9BWG6	926
LUC7L2	SNRNP70	P08621	817
LUC7L2	SNRPD2	P43330	696
LUC7L2	U2AF1	Q01081	691
LUC7L2	SNRPC	P09234	615
LUC7L2	U2AF2	P26368	615
LUC7L2	ZRSR2	Q15696	571
LUC7L2	NCBP3	Q53F19	569
LUC7L2	ATP6V0E2	Q8NHE4	545
LUC7L2	PRPF8	Q6P2Q9	543
LUC7L2	SNRPA	P09012	538
LUC7L2	PRPF40B	Q6NWY9	535
LUC7L2	PRPF39	Q86UA1	530
LUC7L2	HNRNPM	P52272	511
LUC7L2	SRSF5	Q13243	511

IntAct

230 interactions, top by confidence:

A	B	Type	Score
MRFAP1	MORF4L2	psi-mi:“MI:0914”(association)	0.950
EAF1	ELL2	psi-mi:“MI:0914”(association)	0.840
CSNK2A2	EIF3J	psi-mi:“MI:0914”(association)	0.790
LUC7L2	SRSF6	psi-mi:“MI:0915”(physical association)	0.780
SRSF7	LUC7L2	psi-mi:“MI:0915”(physical association)	0.780
SRSF6	LUC7L2	psi-mi:“MI:0915”(physical association)	0.780
APPBP2	LUC7L2	psi-mi:“MI:0915”(physical association)	0.720
LUC7L2	APPBP2	psi-mi:“MI:0915”(physical association)	0.720
LUC7L2	SRPK2	psi-mi:“MI:0217”(phosphorylation reaction)	0.720
SRPK1	LUC7L2	psi-mi:“MI:0217”(phosphorylation reaction)	0.720
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
SCYL1	SEC31A	psi-mi:“MI:0914”(association)	0.710
ARHGEF26	CASK	psi-mi:“MI:0914”(association)	0.690
LUC7L2	NFYA	psi-mi:“MI:0915”(physical association)	0.670
NFYA	LUC7L2	psi-mi:“MI:0915”(physical association)	0.670
LUC7L2	MAP1LC3B	psi-mi:“MI:0915”(physical association)	0.670
CSNK2B	RPS6KA5	psi-mi:“MI:0914”(association)	0.660

BioGRID (528): LUC7L2 (Affinity Capture-MS), LUC7L2 (Two-hybrid), LUC7L2 (Two-hybrid), LUC7L2 (Two-hybrid), LUC7L2 (Two-hybrid), LUC7L2 (Affinity Capture-MS), LUC7L2 (Affinity Capture-MS), LUC7L2 (Affinity Capture-MS), LUC7L2 (Affinity Capture-MS), LUC7L2 (Affinity Capture-MS), LUC7L2 (Affinity Capture-MS), LUC7L2 (Affinity Capture-MS), LUC7L2 (Affinity Capture-MS), LARP7 (Affinity Capture-MS), ZC3H18 (Affinity Capture-MS)

ESM2 similar proteins: A2RVS6, A6QR16, G3V6S8, O22315, O35326, P08621, P09406, P26686, P30352, P62995, P62996, P62997, P84104, Q01130, Q06A98, Q08170, Q09167, Q10021, Q13243, Q13247, Q13595, Q15287, Q16629, Q18409, Q1RMR2, Q23120, Q23121, Q28E41, Q3B7L6, Q3KPW1, Q3MHR5, Q3T106, Q3TWW8, Q3ZBT6, Q4R5N1, Q5NVM8, Q5R1W5, Q5XG24, Q62093, Q62376

Diamond homologs: O95232, Q07508, Q3SX41, Q54XQ8, Q5R8W6, Q5SUF2, Q7TNC4, Q9CYI4, Q9NQ29, Q9USM4, Q9VVI1, Q9Y383, Q09217

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 179 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Transport of Mature Transcript to Cytoplasm	7	21.3×	1e-05
mRNA 3’-end processing	8	12.6×	4e-05
RNA Polymerase II Transcription Termination	7	12.3×	2e-04
mRNA Splicing - Minor Pathway	6	10.8×	1e-03
Transport of Mature mRNA derived from an Intron-Containing Transcript	8	9.8×	2e-04
SPOP-mediated proteasomal degradation of PD-L1(CD274)	5	9.1×	7e-03
Processing of Capped Intron-Containing Pre-mRNA	13	8.5×	3e-06
mRNA Splicing	9	7.9×	2e-04

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of mRNA splicing, via spliceosome	5	23.9×	3e-04
spliceosomal complex assembly	6	22.6×	7e-05
mRNA stabilization	7	16.0×	7e-05
regulation of alternative mRNA splicing, via spliceosome	7	10.7×	6e-04
circadian rhythm	7	10.7×	6e-04
RNA splicing	17	9.4×	5e-09
mRNA splicing, via spliceosome	12	6.9×	7e-05
mRNA processing	12	5.9×	2e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3122 predictions. Top by Δscore:

Variant	Effect	Δscore
7:139341521:GG:G	donor_gain	1.0000
7:139341522:GG:G	donor_gain	1.0000
7:139341523:G:GA	donor_loss	1.0000
7:139345620:GG:G	donor_gain	1.0000
7:139345621:GG:G	donor_gain	1.0000
7:139360318:GGACG:G	donor_gain	1.0000
7:139360319:GACG:G	donor_gain	1.0000
7:139360319:GACGG:G	donor_gain	1.0000
7:139360320:ACG:A	donor_gain	1.0000
7:139360321:CG:C	donor_gain	1.0000
7:139360322:GG:G	donor_gain	1.0000
7:139360323:G:GA	donor_loss	1.0000
7:139360323:G:GG	donor_gain	1.0000
7:139360324:T:A	donor_loss	1.0000
7:139360324:T:G	donor_loss	1.0000
7:139374878:A:AG	acceptor_gain	1.0000
7:139374878:ATGT:A	acceptor_gain	1.0000
7:139374879:T:G	acceptor_gain	1.0000
7:139376054:T:G	acceptor_gain	1.0000
7:139376055:A:AG	acceptor_gain	1.0000
7:139376060:A:AG	acceptor_gain	1.0000
7:139376061:G:GG	acceptor_gain	1.0000
7:139376152:GAACT:G	donor_gain	1.0000
7:139376157:G:GG	donor_gain	1.0000
7:139398595:CCA:C	acceptor_loss	1.0000
7:139398596:CAGAG:C	acceptor_loss	1.0000
7:139398597:A:AG	acceptor_gain	1.0000
7:139398597:A:T	acceptor_loss	1.0000
7:139398598:G:GG	acceptor_gain	1.0000
7:139398598:G:GT	acceptor_gain	1.0000

AlphaMissense

2579 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:139360293:T:A	L11Q	1.000
7:139360293:T:C	L11P	1.000
7:139360302:T:C	L14S	1.000
7:139360307:G:C	G16R	1.000
7:139360307:G:T	G16C	1.000
7:139376106:T:A	C36S	1.000
7:139376106:T:C	C36R	1.000
7:139376107:G:A	C36Y	1.000
7:139376107:G:C	C36S	1.000
7:139376107:G:T	C36F	1.000
7:139376108:C:G	C36W	1.000
7:139376119:T:A	L40H	1.000
7:139376119:T:C	L40P	1.000
7:139376130:T:A	C44S	1.000
7:139376130:T:C	C44R	1.000
7:139376131:G:A	C44Y	1.000
7:139376131:G:C	C44S	1.000
7:139376131:G:T	C44F	1.000
7:139376132:T:G	C44W	1.000
7:139376134:C:A	P45H	1.000
7:139376146:T:C	L49P	1.000
7:139376155:C:T	T52I	1.000
7:139398600:G:C	R53T	1.000
7:139398600:G:T	R53I	1.000
7:139398601:A:C	R53S	1.000
7:139398601:A:T	R53S	1.000
7:139398617:T:A	C59S	1.000
7:139398617:T:C	C59R	1.000
7:139398618:G:C	C59S	1.000
7:139398619:T:G	C59W	1.000

dbSNP variants (sampled 300 via entrez): RS1000078372 (7:139356027 C>T), RS1000087403 (7:139339108 C>T), RS1000154260 (7:139366595 C>T), RS1000162485 (7:139359653 C>A,G,T), RS1000163825 (7:139379124 G>A), RS1000174566 (7:139339878 G>A), RS1000207338 (7:139395430 C>T), RS1000225053 (7:139419382 T>G), RS1000233183 (7:139398894 T>TG), RS1000271296 (7:139407863 T>C), RS1000355744 (7:139404456 C>T), RS1000390397 (7:139384752 T>A), RS1000404486 (7:139345066 C>T), RS1000409575 (7:139404736 G>A,T), RS1000438246 (7:139373043 T>C)

Disease associations

OMIM: gene MIM:613056 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST002875_124	Diisocyanate-induced asthma	1.000000e-06
GCST011197_1	Left ventricular end-systolic volume (MTAG)	2.000000e-06
GCST011203_1	Left ventricular end-diastolic volume (MTAG)	2.000000e-08

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0006995	response to diisocyanate
EFO:0008206	left ventricular systolic function measurement
EFO:0008204	left ventricular diastolic function measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724635 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs6947309	LUC7L2		0.00	0

ChEMBL bioactivities

5 potent at pChembl≥5 of 5 total, top 5 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.75	Kd	1769	nM	CHEMBL3752910
5.75	ED50	1769	nM	CHEMBL3752910
5.59	IC50	2590	nM	MOLIBRESIB
5.37	Kd	4273	nM	CHEMBL5653589
5.37	ED50	4273	nM	CHEMBL5653589

PubChem BioAssay actives

3 with measured affinity, of 10 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148675: Binding affinity to human LUC7L2 incubated for 45 mins by Kinobead based pull down assay	kd	1.7689	uM
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2178874: Inhibition of LUC7L2 (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	2.5900	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148675: Binding affinity to human LUC7L2 incubated for 45 mins by Kinobead based pull down assay	kd	4.2733	uM

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol S	affects expression, increases expression	2
Valproic Acid	decreases expression, decreases methylation	2
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
pyrogallol 1,3-dimethyl ether	affects localization, increases expression, affects cotreatment	1
trichostatin A	affects expression	1
beta-lapachone	decreases expression	1
arsenite	affects binding, decreases reaction	1
sodium arsenite	decreases expression	1
coumarin	increases phosphorylation	1
methacrylaldehyde	affects cotreatment, increases oxidation	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
LDN 193189	increases expression, affects cotreatment	1
bisphenol AF	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Vorinostat	decreases expression	1
Acrolein	affects cotreatment, increases oxidation	1
Arsenicals	decreases expression	1
Caffeine	decreases phosphorylation	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Furaldehyde	decreases expression, affects cotreatment, affects localization	1
Ivermectin	decreases expression	1
Ozone	increases oxidation, affects cotreatment	1
Plant Extracts	affects cotreatment, increases expression	1
Ribonucleotides	affects binding	1
Rotenone	decreases expression	1
Selenium	decreases expression	1
Sodium Chloride	affects cotreatment, affects localization, decreases expression, increases expression	1
Tetrachlorodibenzodioxin	increases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651717	Binding	Binding affinity to human LUC7L2 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3AD	Abcam HEK293T LUC7L2 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.